Occult hepatitis B virus infection: Detection and significance

Digestive Diseases

Volumn 28, Issue 1, 2010, Pages 116-125

  Gerlich, Wolfram H ^a,b   Bremer, Corinna ^a   Saniewski, Mona ^a   Schüttler, Christian G ^a   Wend, Ulrike C ^a   Willems, Wulf R ^a   Glebe, Dieter ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Anti HBc; Anti HBs; Escape mutant; HBsAg; Hepatitis B virus DNA; Nucleic acid amplification technique

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ACUTE HEPATITIS; BLOOD DONOR; GENE MUTATION; HEPADNAVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE DEFICIENCY; LIFE CYCLE; NONHUMAN; NUCLEIC ACID AMPLIFICATION; OCCULT HEPATITIS B; PRIORITY JOURNAL; REVIEW; SCREENING TEST; VIRAL GENETICS; VIREMIA; VIRION; VIRUS DETECTION; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACUTE DISEASE; BLOOD DONORS; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER; VACCINATION; VIREMIA; VIRION; VIRUS ACTIVATION;

EID: 77952569886     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000282074     Document Type: Review

References (32)

1. Schaefer S, Gerlich WH: Structure, replication and laboratory diagnosis of HBV and HDV;in Benhamou JP, Rizzetto R, Reichen R, et al (eds): The Textbook of Hepatology: From Basic Science to Clinical Practice, ed 3. Oxford, Blackwell Publishing, 2007, pp 823-849.
2. Glebe D, Urban S: Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007;13:22-38.
3. Rabe B, Glebe D, Kann M: Lipid-mediated introduction of hepatitis B virus capsids into nonsusceptible cells allows highly efficient replication and facilitates the study of early infection events. J Virol 2006;80:5465-5473.
4. Rabe B, Vlachou A, Panté N, Helenius A, Kann M: Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci USA 2003;100:9849-9854.
5. Nassal M: Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134:235-249.
6. Pairan, Bruss V: Functional surfaces of the hepatitis B virus capsid. J Virol 2009;83:11616-11623.
7. Lambert C, Dorines T, Prange R: Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol 2007;81:9050-9060.
8. Wieland S, Thimme R, Purcell RH, Chisari FV: Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci USA 2004;101:6669-6674.
9. Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH: Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol 2003;69:313-323.
10. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, Craxì A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky JM, Pollicino T, Prati D, Puoti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F: Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-657.
11. Kleinman SH, Busch MP: Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006;36(suppl 1):S23-S29.
12. Furtwängler M, Edwards A, Cyran E, Wend UC, Gerlich WH: Nosokomiale Hepatitis-B-Übertragungen in einer ambulant operierenden Praxis. Dtsch Arztebl 2006;103:1084-1087.
13. Gerlich WH, Wagner F, Chudy M, et al: HBsAg non-reactive HBV infection in blood donors: transmission and pathogenicity. J Med Virol 2007;79, S1:S32-S36.
14. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ;German Red Cross NAT Study Group: Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1558-1566.
15. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D: Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009;49:1621-1629.
16. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, Zuckerman AJ, Thomas HC: Vaccine-induced escape mutant of hepatitis B virus. Lancet 1990;336:325-329.
17. Candotti D, Grabarczyk P, Ghiazza P, Roig R, Casamitjana N, Iudicone P, Schmidt M, Bird A, Crookes R, Brojer E, Miceli M, Amiri A, Li C, Allain JP: Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. J Hepatol 2008;49:537-547.
18. Allain JP, Belkhiri D, Vermeulen M, Crookes R, Cable R, Amiri A, Reddy R, Bird A, Candotti D: Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 2009;49:1868-1876.
19. Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R: Impact ofindividual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. Transfusion 2009;49:1115-1125.
20. González R, Torres P, Castro E, Barbolla L, Candotti D, Koppelman M, Zaaijer HL, Lelie N, Allain JP, Echevarría JM: Efficacy of hepatitis B virus (HBV) DNA screening and characterization of acute and occult HBV infections among blood donors from Madrid, Spain. Transfusion 2009, E-pub ahead of print.
21. Manzini P, Girotto M, Borsotti R, Giachino O, Guaschino R, Lanteri M, Testa D, Ghiazza P, Vacchini M, Danielle F, Pizzi A, Valpreda C, Castagno F, Curti F, Magistroni P, Abate ML, Smedile A, Rizzetto M: Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007;92:1664-1670.
22. Prince AM, Lee DH, Brotman B: Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001;41:329-332.
23. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP: Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol 2008;48:1022-1025.
24. Lau GK: Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152-162.
25. Gärtner BC, Jung W, Welsch C, Fischinger, JS, Zeuzem S, Mueller-Lantzsch N, Wend UC, Gerlich WH: Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. J Clin Virol 2007;38:146-148.
26. Westhoff TH, Jochimsen F, Schmittel A, Stöffler-Meilicke M, Schäfer JH, Zidek W, Gerlich WH, Thiel E: Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1930.
27. Awerkiew S, Däumer M, Reiser M, Wend UC, Pfister H, Kaiser R, Willems WR, Gerlich WH: Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007;38:83-86.
28. Miyagawa M, Minami M, Fujii K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasui K, Itoh Y, Taniwaki M, Okanoue T, Yoshikawa T: Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol 2008;80:2069-2078.
29. Fitzsi mons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, Duval B, Jilg W, Böcher WO, Lu SN, Akarca U, Lavanchy D, Goldstein S, Banatvala J, Damme PV: Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005;23:4158-4166.
30. Gerlich WH: Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol 2006;36(suppl 1): S18- S22.
31. Stramer SL, Townsend RL, Foster GA, Brodsky JP, Linnen JM, Coleman PF, Allain JP, Gerlich WH: The role of hepatitis B virus surface proteins in immune protection and escape - occult hepatitis B virus infections in vaccinated and non-vaccinated blood donors. J Clin Virol 2009;46(suppl 1):51.
32. Skrastina D, Bulavaite A, Sominskaya I, Kovalevska L, Ose V, Priede D, Pumpens P, Sasnauskas K: High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers. Vaccine 2008;26:1972-1981.